An interventional study of CPAP in Afib, Sleep Apnea Syndrome, Obstructive and CPAP, sponsored by The Cleveland Clinic. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Atrial Fibrillation by The Cleveland Clinic — 10 open to participants now, 11 under way, 1 of them phase 3. Atrial Fibrillation · The Cleveland Clinic.
Among the 26 studies in Atrial Fibrillation by The Cleveland Clinic, this one is the 9th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 22nd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →10 of the 26 studies in Atrial Fibrillation by The Cleveland Clinic are open now, in 1 country. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 22+
The Cleveland Clinic · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 90 across the 13 interventional studies, 60 across the 13 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
4 of the studies in Atrial Fibrillation by The Cleveland Clinic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07893275Phase 3The Cleveland ClinicSGB for Prevention of Postop A-Fib After Cardiac SurgeryTrial | 2027-10 |
| NCT07087587The Cleveland ClinicSleep Apnea Triggers of Atrial Fibrillation: N-of-1 Randomized Control Trial (SPARTA): | 2026-12-31 |
| NCT06802081The Cleveland ClinicTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation | 2026-12-31 |
| NCT07083115The Cleveland ClinicDeveloping MRI Technologies for Atrial Fibrillation | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 26 studies in Atrial Fibrillation by The Cleveland Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A pilot N-of-1 randomized controlled trial evaluating the effectiveness of a personalized CPAP intervention in reducing atrial fibrillation (AF) burden and improving AF-related quality of life in patients with moderate to severe obstructive sleep apnea (OSA).
This pilot study investigates whether continuous positive airway pressure (CPAP) therapy reduces AF burden in patients with paroxysmal AF and moderate to severe OSA. Using an N-of-1 randomized crossover design, each participant undergoes alternating 2-week periods with and without CPAP over 3 months. Data on AF episodes are collected from implantable cardiac devices, and AF-related quality of life is assessed using the AFEQT questionnaire. The study also examines CPAP adherence and its correlation with changes in AF burden. Results will inform the design of a larger trial and address gaps in current evidence on the cardiovascular effects of sleep apnea therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant undergoes alternating 2-week periods of CPAP treatment and no treatment over approximately 13 weeks. This personalized intervention evaluates changes in AF burden and quality of life, with patients serving as their own controls.
Device: CPAP
CPAP will be randomized 2 weeks on 2 weeks off for 12 weeks total
Change in Average Daily AF Burden (%)
Percentage change in average daily atrial fibrillation burden, measured via implantable device data, comparing CPAP and non-CPAP periods.
Time frame: Up to 13 weeks (duration of each patient's participation)
Change in Atrial Fibrillation-Related Quality of Life (AFEQT Score)
Change in patient-reported AFEQT scores between CPAP and non-CPAP periods to assess quality-of-life impact.
Time frame: Baseline, week 4, week 8, and final visit (~13 weeks)
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 16 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.